PDL BioPharma, Inc.
<b>Headquarters and R&D</b>
1400 Seaport Boulevard
430 articles with PDL BioPharma, Inc.
PDL BioPharma, Inc. announced that the Company will hold its annual meeting of stockholders on Thursday, June 20, 2019, at 3:00 p.m. Pacific Time for all stockholders of record on April 26, 2019.
Transaction supports strategy of investing in near-commercial stage products with potential to create significant shareholder value Provides Evofem capital to prepare for the successful launch of Amphora® (L-lactic acid, citric acid, and potassium bitartrate), a novel, investigational non-hormonal, on-demand female contraceptive
Evofem Biosciences Enters into Financing Agreement for up to $80 Million, Closes First Tranche of Strategic Investment from PDL BioPharma
Evofem Biosciences, Inc. (NASDAQ: EVFM) ("Evofem"), today announced it has entered into a securities purchase agreement pursuant to which Evofem can raise up to $80 million through a private placement of common stock from new and existing investors, including a strategic investment from PDL BioPharma, Inc.
The session will be webcast live and will occur on Tuesday, April 9, 2019, at 10:50 a.m. British Standard Time.
PDL BioPharma, Inc. reports financial results for the three and 12 months ended December 31, 2018
PDL BioPharma, Inc. announces that Peter Garcia, PDL's vice president and chief financial officer, will participate in a series of investor meetings at the 31st Annual Roth Conference being held March 17-19 at the Ritz-Carlton Laguna Niguel in Dana Point, Calif.
PDL BioPharma, Inc. announced that it will release its 2018 fourth quarter and full year financial results for the period ended December 31, 2018, on Thursday, March 14, 2019, after market close.
PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet, PDL's president and chief executive officer, and Peter Garcia, PDL's chief financial officer, will present at the Cowen 39th Annual Health Care Conference in New York City.
PDL BioPharma Announces Launch of an Authorized Generic of Tekturna® (aliskiren) in Partnership with Prasco Laboratories
PDL BioPharma, Inc. announces the U.S. commercial launch of an authorized generic of Tekturna®, aliskiren hemifumarate 150 mg and 300 mg tablets.
The session will be webcast live and will occur on Tuesday, November 27, 2018, at 1:50 p.m. EST.
Announces CEO succession plan
PDL BioPharma, Inc. today announced that it will release its third quarter financial results for the period ended September 30, 2018, on Tuesday, November 6, 2018, after market close.
Mr. Imbrogno brings to PDL more than 30 years of public accounting and financial reporting experience and will report to Vice President and Chief Financial Officer, Peter Garcia.
Purchases may be made in open-market transactions, in block transactions on or off an exchange,
Expresses Serious Concerns Regarding PDL's Misguided Acquisition Strategy, Which Has Destroyed Shareholder Value
PDL BioPharma, Inc. announces that John McLaughlin, PDL's chief executive officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference.
PDL BioPharma, Inc. reports financial results for the three and six months ended June 30, 2018
PDL BioPharma Acquires Depomed's Remaining 50% Interest in Royalties and Milestones on Type 2 Diabetes Products
PDL BioPharma, Inc. announces an amendment to the Royalty Purchase and Sale Agreement with Depomed, Inc. under which PDL acquired all of Depomed's remaining rights to royalties and milestones payable on sales of type 2 diabetes products licensed by Depomed for up to $20 million.
PDL BioPharma, Inc. announced that the Company will release its second quarter financial results for the period ended June 30, 2018, on Wednesday, August 8, 2018, after market close.
Election effective June 22, 2018 and increasing the number of directors to nine.